Kindeva reveives an investment support of US$42 million(£33m) from the UK government to enhanc inhaler manufacturing and sustainability.
The investment facilitates inhaler manufacturing across two sites in the United Kingdom, specifically in Loughborough and Clitheroe.
The collaborative investment aims to enhance its ability to produce the next generation of environmentally-friendly pressurised metred-dose inhalers (pMDIs) and to provide ongoing advancements in treatments for respiratory illnesses on a global scale.
This financial support will enable to broaden its capabilities and production capacity. This expansion will involve pharmaceutical corporations worldwide to introduce the latest generation of green inhalers to the patients.
Furthermore, this investment supports:
Type New Construction
Budget US$42 million(£33m)